Rajbeer S Sangha1, Andrew M Naidech1, Carlos Corado1, Sameer A Ansari1, Shyam Prabhakaran2. 1. From the Departments of Neurology (R.S.S., A.M.N., C.C., S.P.) and Radiology (S.A.A.), Northwestern Memorial Hospital, Chicago, IL. 2. From the Departments of Neurology (R.S.S., A.M.N., C.C., S.P.) and Radiology (S.A.A.), Northwestern Memorial Hospital, Chicago, IL. shyam.prabhakaran@northwestern.edu.
Abstract
BACKGROUND AND PURPOSE: Since the SAMMPRIS trial (Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis), aggressive medical management (AMM), which includes dual antiplatelet therapy (DAPT) and high-dose statin (HDS) therapy, is recommended for patients with symptomatic intracranial atherosclerotic disease. However, limited data on the real-world application of this regimen exist. We hypothesized that recurrent stroke risk among patients treated with AMM is similar to the medical arm of the SAMMPRIS cohort. METHODS: Using a prospective registry, we identified all patients admitted between August 2012 and March 2015 with (1) confirmed ischemic stroke or transient ischemic attack; (2) independently adjudicated symptomatic intracranial atherosclerotic disease; and (3) follow-up at 30 days. We analyzed 30-day risk of recurrent ischemic stroke stratified by treatment: (1) AMM: DAPT plus HDS therapy, (2) HDS alone, and (3) DAPT alone. We also assessed 30-day risk among patients who met prespecified SAMMPRIS eligibility criteria. RESULTS: Among 99 patients who met study criteria (51.5% male, 54.5% black, mean age 68.2±11.2 years), 49 (48.5%) patients were treated with AMM, 69 (69.7%) with DAPT, and 73 (73.7%) with HDS therapy. At 30 days, 20 (20.2%) patients had recurrent strokes in the territory of stenosis. Compared with the risk in the medical arm of SAMMPRIS (4.4%), the 30-day risk of recurrent stroke was 20.4% in AMM patients, 21.5% in HDS patients, 22.4% in DAPT patients, and 23.2% in SAMMPRIS-eligible patients (all P<0.001). CONCLUSIONS: Recurrent stroke risk within 30 days in patients with symptomatic intracranial atherosclerotic disease was higher than that observed in the medical arm of SAMMPRIS even in the subgroup receiving AMM. Replication of the SAMMPRIS findings requires further prospective study.
BACKGROUND AND PURPOSE: Since the SAMMPRIS trial (Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis), aggressive medical management (AMM), which includes dual antiplatelet therapy (DAPT) and high-dose statin (HDS) therapy, is recommended for patients with symptomatic intracranial atherosclerotic disease. However, limited data on the real-world application of this regimen exist. We hypothesized that recurrent stroke risk among patients treated with AMM is similar to the medical arm of the SAMMPRIS cohort. METHODS: Using a prospective registry, we identified all patients admitted between August 2012 and March 2015 with (1) confirmed ischemic stroke or transient ischemic attack; (2) independently adjudicated symptomatic intracranial atherosclerotic disease; and (3) follow-up at 30 days. We analyzed 30-day risk of recurrent ischemic stroke stratified by treatment: (1) AMM: DAPT plus HDS therapy, (2) HDS alone, and (3) DAPT alone. We also assessed 30-day risk among patients who met prespecified SAMMPRIS eligibility criteria. RESULTS: Among 99 patients who met study criteria (51.5% male, 54.5% black, mean age 68.2±11.2 years), 49 (48.5%) patients were treated with AMM, 69 (69.7%) with DAPT, and 73 (73.7%) with HDS therapy. At 30 days, 20 (20.2%) patients had recurrent strokes in the territory of stenosis. Compared with the risk in the medical arm of SAMMPRIS (4.4%), the 30-day risk of recurrent stroke was 20.4% in AMMpatients, 21.5% in HDS patients, 22.4% in DAPTpatients, and 23.2% in SAMMPRIS-eligible patients (all P<0.001). CONCLUSIONS: Recurrent stroke risk within 30 days in patients with symptomatic intracranial atherosclerotic disease was higher than that observed in the medical arm of SAMMPRIS even in the subgroup receiving AMM. Replication of the SAMMPRIS findings requires further prospective study.
Authors: Ralph L Sacco; Scott E Kasner; Joseph P Broderick; Louis R Caplan; J J Buddy Connors; Antonio Culebras; Mitchell S V Elkind; Mary G George; Allen D Hamdan; Randall T Higashida; Brian L Hoh; L Scott Janis; Carlos S Kase; Dawn O Kleindorfer; Jin-Moo Lee; Michael E Moseley; Eric D Peterson; Tanya N Turan; Amy L Valderrama; Harry V Vinters Journal: Stroke Date: 2013-05-07 Impact factor: 7.914
Authors: E Feldmann; J L Wilterdink; A Kosinski; M Lynn; M I Chimowitz; J Sarafin; H H Smith; F Nichols; J Rogg; H J Cloft; L Wechsler; J Saver; S R Levine; C Tegeler; R Adams; M Sloan Journal: Neurology Date: 2007-04-04 Impact factor: 9.910
Authors: L B Goldstein; M R Jones; D B Matchar; L J Edwards; J Hoff; V Chilukuri; S B Armstrong; R D Horner Journal: Stroke Date: 2001-05 Impact factor: 7.914
Authors: Marc I Chimowitz; Michael J Lynn; Colin P Derdeyn; Tanya N Turan; David Fiorella; Bethany F Lane; L Scott Janis; Helmi L Lutsep; Stanley L Barnwell; Michael F Waters; Brian L Hoh; J Maurice Hourihane; Elad I Levy; Andrei V Alexandrov; Mark R Harrigan; David Chiu; Richard P Klucznik; Joni M Clark; Cameron G McDougall; Mark D Johnson; G Lee Pride; Michel T Torbey; Osama O Zaidat; Zoran Rumboldt; Harry J Cloft Journal: N Engl J Med Date: 2011-09-07 Impact factor: 91.245
Authors: Michael F Waters; Brian L Hoh; Michael J Lynn; Hyung-Min Kwon; Tanya N Turan; Colin P Derdeyn; David Fiorella; Anna Khanna; Tiffany O Sheehan; Bethany F Lane; Scott Janis; Jean Montgomery; Marc I Chimowitz Journal: JAMA Neurol Date: 2016-03 Impact factor: 18.302
Authors: Adam de Havenon; Pooja Khatri; Shyam Prabhakaran; Sharon D Yeatts; Cecilia Peterson; Daniel Sacchetti; Matthew Alexander; Shawna Cutting; Brian Mac Grory; Karen Furie; David S Liebeskind; Shadi Yaghi Journal: J Neuroimaging Date: 2020-06-24 Impact factor: 2.486
Authors: Tanya N Turan; Jenifer H Voeks; Marc I Chimowitz; Ana Roldan; Todd LeMatty; William Haley; Maria Lopes-Virella; Seemant Chaturvedi; Michael Jones; Donald Heck; George Howard; Brajesh K Lal; James F Meschia; Thomas G Brott Journal: Stroke Date: 2020-09-21 Impact factor: 7.914
Authors: Shadi Yaghi; Adam de Havenon; Tristan Honda; Jason D Hinman; Radoslav Raychev; Latisha K Sharma; Song Kim; Edward Feldmann; Jose G Romano; Shyam Prabhakaran; David S Liebeskind Journal: J Neuroimaging Date: 2021-02-10 Impact factor: 2.486
Authors: Shyam Prabhakaran; David S Liebeskind; George Cotsonis; Azhar Nizam; Edward Feldmann; Rajbeer S Sangha; Iszet Campo-Bustillo; Jose G Romano Journal: Stroke Date: 2021-04-19 Impact factor: 10.170
Authors: Amol Mehta; Farid Khasiyev; Clinton B Wright; Tatjana Rundek; Ralph L Sacco; Mitchell S V Elkind; Jose Gutierrez Journal: Stroke Date: 2022-02-02 Impact factor: 10.170
Authors: Udit Saraf; Shyam Prabhakaran; K Arun; Ahmed Babiker; Adithyan Rajendran; Chandrasekharan Kesavadas; P N Sylaja Journal: Ann Indian Acad Neurol Date: 2020-06-05 Impact factor: 1.383